SBFM
NASDAQSunshine Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.22+0.00 (+2.10%)
01:30 PM06:00 PM
News · 26 weeks48-9%
2026-04-192026-10-11
Mix3190d
- SEC Filings14(45%)
- Market11(35%)
- Other5(16%)
- Insider1(3%)
Latest news
25 items- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 8-K filed by Sunshine Biopharma Inc.8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 8-K filed by Sunshine Biopharma Inc.8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 424B4 filed by Sunshine Biopharma Inc.424B4 - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Closing of up to $20.4 Million Public Offering$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 10,909,082 Common Un
- NEWSSunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingFORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consists of 10,909,083 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warr
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care PortfolioLaunch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgeryGlobal ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataInteloCommercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is p
- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling StudiesNanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medication
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 424B3 filed by Sunshine Biopharma Inc.424B3 - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSHealth Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular ConditionsFORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart.Atenolol is primarily indicated for:Hypertension Manag
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- PRA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks like and help it go after those cancer cells. That matters in lung cancer because every tumor can be different, and some eventually learn how to get around existing treatments. Researchers are now looking at whether personalized mRNA vaccines can work alongside today’s immunotherapies to give the immune system a
- NEWSSunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung CancerK1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma modelsProgram targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancersNext phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1
- NEWSSunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug MarketGlobal anti-hypertensive drug market projected to reach $37.24 billion by 2034Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunctionSunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
- INSIDERDirector Natan David was granted 58,300 shares, increasing direct ownership by 583% to 68,300 units (SEC Form 4)4 - Sunshine Biopharma Inc. (0001402328) (Issuer)
- NEWSSunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global MarketSunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengthsLaunch expands Sunshine Biopharma's growing portfolio of essential prescription medicationsGlobal Amoxicillin market projected to reach approximately $6.4 billion by 2031 FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to
SBFM FAQ
5 questionsWhat does Sunshine Biopharma Inc. do?
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a...Where does SBFM stock trade?
Sunshine Biopharma Inc. (SBFM) is listed on NASDAQ.What sector and industry is SBFM in?
Sunshine Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SBFM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SBFM side-by-side with any of them on Quantisnow.How can I track SBFM on Quantisnow?
Quantisnow aggregates Sunshine Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBFM to receive live email and push alerts on every new disclosure.